NVasc

NVasc is a regenerative medicine company focused on developing innovative solutions for patients suffering from severe vascular diseases, particularly critical limb ischemia. The company's core technology involves a proprietary microvascular tissue engineering platform designed to restore blood flow in tissues where traditional surgical or endovascular interventions have failed. By utilizing a combination of advanced biomaterials and cellular components, NVasc aims to create functional microvascular networks that integrate with the patient's existing circulatory system. Their lead programs target peripheral artery disease and chronic non-healing wounds, addressing a significant unmet need in vascular health. The company is currently advancing its lead candidates through pre-clinical validation to support future clinical trials.